Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
(OP:
MDXXF
)
0.1222
+0.0153 (+14.31%)
Streaming Delayed Price
Updated: 3:53 PM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MDXXF
PharmAla Contracts with Partner to Act as US Distributor
March 24, 2025
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
February 27, 2025
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
February 06, 2025
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
January 20, 2025
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
October 21, 2024
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
April 05, 2024
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities
From
PharmAla Biotech
Via
GlobeNewswire
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
March 27, 2024
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities
From
PharmAla Biotech
Via
GlobeNewswire
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
March 20, 2024
Novel MDMA-Like Drug Could Be Used for Numerous Neurological and Psychiatric Indications
From
PharmAla Biotech
Via
GlobeNewswire
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
March 18, 2024
PharmAla now first company to supply both MDMA and Psilocybin into the Australian Market
From
PharmAla Biotech
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.